Strategic Partners A/S - Capital/Financing Update 2017

Orphazyme A/S: No termination or withdrawal of Orphazyme's IPO

Orphazyme A/S: No termination or withdrawal of Orphazyme's IPO


Company announcement No. 11/2017	Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 20 November 2017

NOT
FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR CANADA, AUSTRALIA, JAPAN
OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

With reference to company announcements no.
2/2017 dated 6 November 2017 and no. 5/2017 dated 16 November 2017, Orphazyme
A/S ("Orphazyme") today announces that it has received confirmation from the
Joint Global Coordinators, on behalf of the managers, acting as underwriters
that none of the termination rights of the underwriters provided for in the
underwriting agreement dated 6 November 2017 have been invoked. The Initial
Public Offering (the "IPO") and admission to trading and official listing of
Orphazyme on Nasdaq Copenhagen A/S ("Nasdaq Copenhagen") will therefore not be
terminated or withdrawn.

Subject to the registration of the new shares
subscribed for in connection with the IPO with the Danish Business Authority,
the IPO is considered completed with the admission to trading and official
listing on Nasdaq Copenhagen becoming unconditional. A separate company
announcement will be published in this regard.

Bank
Syndicate

Carnegie
and Danske Bank are acting as Joint Global Coordinators and Joint Bookrunners,
and Oddo BHF SCA is acting as Co-Lead Manager for the IPO.

For
additional information, please contact

Orphazyme

Anders
Hinsby, CEO +45 31 44 31 39

About
Orphazyme

Orphazyme
is a Danish biotech company with a late stage orphan drug pipeline, developing
new treatment options for orphan protein misfolding diseases. The Company was
founded in 2009 based on early scientific discovery in heat shock proteins
("HSPs"). Since inception, the Company has translated scientific discovery into
a late stage clinical development programme. The Company is headquartered in
Copenhagen and currently has 30 employees.

The
Company focuses on severe and mostly fatal diseases with a high unmet need, and
with a particularly strong commitment to neuromuscular diseases and a group of
severe genetic diseases called lysosomal storage diseases. The Company plans to
pursue development of its lead candidate through to registration in the EU and
the United States after which launch and commercialisation is expected to be
undertaken by the Company.

The
lead candidate arimoclomol is in development as a potential treatment for four
orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis
("sIBM") and Amyotrophic Lateral Sclerosis ("ALS"), and two lysosomal storage
diseases, Niemann Pick type C ("NPC") and Gaucher disease.

Important
notice

This announcement is not an offer to sell or a
solicitation of any offer to buy any securities issued by Orphazyme A/S (the
"Company") in any jurisdiction where such offer or sale would be unlawful and
the announcement and the information contained herein are not for distribution
or release, directly or indirectly, in or into such jurisdictions.

This announcement and the information contained
herein are not for distribution in or into the United States of America
(including its territories and possessions, any state of the United States of
America and the District of Columbia) (the "United States"). This document does
not constitute, or form part of, an offer to sell, or a solicitation of an
offer to purchase, any securities of the Company in the United States. The
securities of the Company have not been and will not be registered under the
U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be
offered or sold within the United States absent registration or an applicable
exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act. There is no intention to register any
securities referred to herein in the United States or to make a public offering
of the securities in the United States.

In any member state of the European Economic
Area ("EEA Member State"), other than Denmark, that has implemented Directive
2003/71/EC as amended (together with any applicable implementing measures in
any member State, the "Prospectus Directive"), this communication is only
addressed to and is only directed at investors in that EEA Member State who
fulfil the criteria for exemption from the obligation to publish an offering
memorandum, including qualified investors, within the meaning of the Prospectus
Directive as implemented in each such EEA Member State.

This announcement is only being distributed to
and is only directed at (i) persons who are outside the United Kingdom or (ii)
to investment professionals falling within Article 19(5) of the U.K. Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or
(iii) high net worth entities falling within Article 49(2)(a) - (d) of the
Order (the persons de-scribed in (i) through (iii) above together being
referred to as "relevant persons"). The securities are only available to, and
any invitation, offer or agreement to subscribe, purchase or otherwise acquire
such securities will be engaged in only with, relevant persons. Any person who
is not a relevant person should not act or rely on this announcement or any of
its contents.

In connection with the offering, Danske Bank
A/S (the "Stabilising Manager") (or persons acting on behalf of the Stabilising
Manager) may over-allot securities or effect transactions with a view to
supporting the market price of the securities at a level higher than that which
might otherwise prevail. However, there is no assurance that the Stabilising
Manager (or persons acting on behalf of the Stabilising Manager) will undertake
stabilisation. Any stabilisation action may begin on or after the date of
commencement of trading and official listing of the securities on Nasdaq
Copenhagen A/S and, if begun, may be ended at any time, but it must end no
later than 30 days after the date of commencement of trading and official
listing of the securities.

Attachments: